Affordable Care Act

Five things for pharma marketers to know: Tuesday, November 29, 2016

Five things for pharma marketers to know: Tuesday, November 29, 2016

By

Trump selects Price as head of HHS; Warren criticizes 21st Century Cures; GSK CEO says companies will have to get used to making less money

10 Things for Trump to Consider When It Comes to Healthcare

10 Things for Trump to Consider When It Comes to Healthcare

Peter Pitts calls for Trump to eliminate the Independent Payment Advisory Board and direct the FDA to issue guidance on off-label communications.

Five things for pharma marketers to know: Thursday, November 17, 2016

Five things for pharma marketers to know: Thursday, November 17, 2016

By

Former Valeant and Philidor execs arrested; at least 1 million enroll in 2017 exchange plans; mobile game helps scientists study dementia

Five things for pharma marketers to know: Friday, November 11, 2016

Five things for pharma marketers to know: Friday, November 11, 2016

By

Trump says he will reform the FDA; pharmaceutical M&A expected to pick up; superbug causing infections in cystic-fibrosis patients

How Ascension's Nick Ragone is rebranding one of the biggest U.S. health systems

How Ascension's Nick Ragone is rebranding one of the biggest U.S. health systems

By

The health system is one of the largest in the country. Most of Ascension's hospitals, Ragone says, used to operate almost independently from each other and the company's headquarters.

Five things for pharma marketers to know: Monday, November 7, 2016

Five things for pharma marketers to know: Monday, November 7, 2016

By

Bayer submits Stivarga to FDA for liver-cancer indication; emails show FDA's divisiveness over Duchenne drug approval; insurers want new president to address ACA financial risks

Trump or Clinton? Either May Lead to Better Mental Healthcare

Trump or Clinton? Either May Lead to Better Mental Healthcare

Despite political rifts that have blocked progress on so many other fronts, Congress has managed to lay the groundwork for clear steps forward in mental health.

Health exchanges, Obama administration challenged by recent insurer exits

Health exchanges, Obama administration challenged by recent insurer exits

By

The pull-back of insurance providers has left state-run health exchanges and the Obama administration facing a difficult communications challenge.

Clinton or Trump? Either Way, Change Is Coming

Clinton or Trump? Either Way, Change Is Coming

Donald Trump and Hillary Clinton offer clear contrasts on the issues of the Affordable Care Act, entitlement reform, and drug pricing.

Five things for pharma marketers to know: Wednesday, March 2, 2016

Five things for pharma marketers to know: Wednesday, March 2, 2016

By

The doc shortage may be due, in part, to changing marriage patterns; Olympus settles anti-kickback case; U.K. says Imbruvica is too expensive

3 Ways Insurers Can Integrate Digital Strategies into the Marketing Mix

3 Ways Insurers Can Integrate Digital Strategies into the Marketing Mix

As more healthcare patients move online, it is imperative that marketers use the right marketing strategy to keep them engaged—a strategy that should always include digital advertising.

Q&A: Why McCann Health set up a pharmacy focused agency

Q&A: Why McCann Health set up a pharmacy focused agency

By

A Q&A with Sandra Carey, president of the McCann Pharmacy Initiative, on the move to push pharmacy to the forefront.

Market Access: Looking Back, Looking Ahead

Market Access: Looking Back, Looking Ahead

Securing market access has become significantly more challenging for pharma marketers.

What if Hospital Meant Hospitality?

What if Hospital Meant Hospitality?

How to bring an enhanced customer experience to the healthcare industry

Physicians Interactive acquires Quantia

Physicians Interactive acquires Quantia

By

The deal is expected to complement the company's digital health platform.

Study: 10 medications will cost US $50 billion over 10 years

Study: 10 medications will cost US $50 billion over 10 years

By

An analysis by Avalere Health says 10 breakthrough therapy drugs will account for billions in spending.

PCORI explains how it will release comparative-effectiveness findings

PCORI explains how it will release comparative-effectiveness findings

By

The organization plans to publish a scientific and a lay abstract detailing study findings

High deductibles, costs keep patients away

High deductibles, costs keep patients away

By

More cost data for the file the latest data shows that up-front healthcare costs are prompting many patients to delay office visits.

HHS dials back ACA enrollment forecast

The CBO projected 13 million enrolled in 2015, but its projections were based before final 2014 numbers were in.

Drug spend will continue to rise through 2023

Drug spend will continue to rise through 2023

By

The numbers folks at the Centers for Medicare and Medicaid Services anticipate sluggish growth in US healthcare spend, but prescriptions look ready to take off.

White House proposes Hobby Lobby alternative

A proposal by the Obama administration Friday seeks to keep contraception accessible and coverage approval at arm's length for employees of religious non-profits.

Employers like "skinny" health plans

These healthcare plans allow employees and employers to avoid ACA penalties but provide little coverage.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

Healthcare reform lawsuits continue

With just days before the enrollment deadline, courts are pulsing with legal opposition to heatlhcare reform insurance subsidies.

HHS extends insurance deadline

The March 31 deadline for health insurance is not the be-all-and-end-all, while a survey found that 50% of the uninsured intend to stay that way.

HHS releases exchange enrollment data

The program has yet to reach magnet status among cheaper, youthful patients.

Business briefs: Lilly, Novartis, Activartis, plus policy news

Eli Lilly and Boehringer Ingelheim submit a glargine biosimilar to the EMA; Novartis pipeline claims an Enbrel-superior treatment; Activartis med gets orphan drug status; generics makers may have to pay more attention to labels; Administration tweaks healthcare reform implementation over the long weekend.

Researchers spot $213B of wasteful drug spending

Researchers spot $213B of wasteful drug spending

By

For a country bent on healthcare cost control, findings represent an opportunity: authors say nearly 8% of the nation's total outlay could have been avoided.

Business Briefs: Amgen and Astellas; GSK; Teva; Novo; Livestrong

Amgen and Astellas team up to take on Japan; GSK acquires Swiss vaccine developer's innovative platform; Ireland makes generic switches easier; Novo backs wet AMD therapy; Nike ditches Livestrong

FDA widens scope of DTC impact survey

By

The agency is revisiting the impact DTC advertising can have on healthcare. What's new: NPs and PAs are being asked for input.

OPINION

Email Newsletters